FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2278494804> ?p ?o ?g. }

• W2278494804 endingPage "8031" @default.
• W2278494804 startingPage "8031" @default.
• W2278494804 abstract "8031 Background: MM remains incurable despite recent therapeutic advances. Although novel treatment combinations have improved outcome, new combinations are urgently needed. V, an oral histone deacetylase inhibitor, enhances anti-MM activity of other small molecule pro-apoptotics, with preclinical synergy seen when combined with L. This ongoing phase I multicenter, open-label study evaluated V plus L and D. Maximum tolerated dose (MTD; primary objective), safety, tolerability, and response rate (RR) were assessed. Methods: Relapsed and/or refractory MM pts were enrolled into 1 of 5 escalating doses of combination regimen using standard 3+3 design. Toxicity and response were evaluated using NCI c3.0 CTC and EBMT/UC. Results: Median prior therapies was 3 (range 1-12, N=31). Most pts received prior bortezomib (65%), thalidomide (68%), or L (45%). The majority ofadverse events(AEs) were mild/moderate; most common ≥G3 drug-related AEs (all cycles) were neutropenia (23%), thrombocytopenia (16%), diarrhea (13%), and fatigue (10%). One dose-limiting toxicity was seen (Table), with MTD not reached. Of 30 pts evaluable for efficacy, 26 (87%) experienced ≥ stable disease (SD); best single responses were 2 complete, 2 very good partial (VGPR), 10 partial (PR), 5 minimal (MR), 7 SD, and 4 progressive disease, for RR (≥ MR) of 63%. Of 13 evaluable pts who received prior L, ≥ SD was seen in 9 (69%), with 1 VGPR, 3 PR, 1 MR, and 4 SD, for RR (≥MR) of 38%. Conclusions: Preliminary results suggest V, L, and D may be a convenient, effective, and generally well tolerated oral regimen for relapsed/refractory MM pts. Activity was also seen in pts who received prior L. Further analysis of this study is ongoing and a phase II study is planned. Dosing Dose level (DL) V(mg qd)7 days on 7 off(days 1-7 and 15-21) L(mg qd)× 21 days(day 1-21) D(mg qd)(days 1, 8, 15, and 22) Evaluable for DLT† Maximum cycles‡ DLT 1 300 10 40 3 19 0 2 400 10 40 3 15 0 3 400 15 40 3 11 0 4 400 20 40 3 12 0 5 400 25 40 6 (+10§) 12 Diarrhea (G3) Cycles: 28 days. Concomitant daily aspirin recommended. † 10/31 pts (across all DLs) remain ongoing. ‡ Maximum treatment cycle for which ≥1 pt received ≥1 dose. § 10-pt expansion cohort enrolled at DL 5 with no formal DLT assessment. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celgene, Dana-Farber Cancer Institute, Merck Bristol-Myers Squibb, Celgene, Merck, Millennium, Novartis, Ortho Biotech, Pharmion Merck Celgene, Janssen-Ortho, Merck, Millennium, Novartis, Onyx, Ortho Biotech, Pharmion Celgene, Gloucester Pharmaceuticals, Merck, Merck Serono, Millennium, Novartis" @default.
• W2278494804 created "2016-06-24" @default.
• W2278494804 creator A5004747253 @default.
• W2278494804 creator A5012712111 @default.
• W2278494804 creator A5023752321 @default.
• W2278494804 creator A5032464400 @default.
• W2278494804 creator A5043526996 @default.
• W2278494804 creator A5055012214 @default.
• W2278494804 creator A5055929208 @default.
• W2278494804 creator A5062406723 @default.
• W2278494804 creator A5081147730 @default.
• W2278494804 creator A5014959415 @default.
• W2278494804 date "2010-05-20" @default.
• W2278494804 modified "2023-09-25" @default.
• W2278494804 title "Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM)." @default.
• W2278494804 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.8031" @default.
• W2278494804 hasPublicationYear "2010" @default.
• W2278494804 type Work @default.
• W2278494804 sameAs 2278494804 @default.
• W2278494804 citedByCount "6" @default.
• W2278494804 countsByYear W22784948042012 @default.
• W2278494804 countsByYear W22784948042013 @default.
• W2278494804 crossrefType "journal-article" @default.
• W2278494804 hasAuthorship W2278494804A5004747253 @default.
• W2278494804 hasAuthorship W2278494804A5012712111 @default.
• W2278494804 hasAuthorship W2278494804A5014959415 @default.
• W2278494804 hasAuthorship W2278494804A5023752321 @default.
• W2278494804 hasAuthorship W2278494804A5032464400 @default.
• W2278494804 hasAuthorship W2278494804A5043526996 @default.
• W2278494804 hasAuthorship W2278494804A5055012214 @default.
• W2278494804 hasAuthorship W2278494804A5055929208 @default.
• W2278494804 hasAuthorship W2278494804A5062406723 @default.
• W2278494804 hasAuthorship W2278494804A5081147730 @default.
• W2278494804 hasConcept C121332964 @default.
• W2278494804 hasConcept C126322002 @default.
• W2278494804 hasConcept C141071460 @default.
• W2278494804 hasConcept C142424586 @default.
• W2278494804 hasConcept C197934379 @default.
• W2278494804 hasConcept C2776063141 @default.
• W2278494804 hasConcept C2776364478 @default.
• W2278494804 hasConcept C2776694085 @default.
• W2278494804 hasConcept C2777063308 @default.
• W2278494804 hasConcept C2777478702 @default.
• W2278494804 hasConcept C2778375690 @default.
• W2278494804 hasConcept C2778822529 @default.
• W2278494804 hasConcept C2778850193 @default.
• W2278494804 hasConcept C2779609412 @default.
• W2278494804 hasConcept C2780401358 @default.
• W2278494804 hasConcept C2781413609 @default.
• W2278494804 hasConcept C29730261 @default.
• W2278494804 hasConcept C31760486 @default.
• W2278494804 hasConcept C71924100 @default.
• W2278494804 hasConcept C87355193 @default.
• W2278494804 hasConcept C90924648 @default.
• W2278494804 hasConceptScore W2278494804C121332964 @default.
• W2278494804 hasConceptScore W2278494804C126322002 @default.
• W2278494804 hasConceptScore W2278494804C141071460 @default.
• W2278494804 hasConceptScore W2278494804C142424586 @default.
• W2278494804 hasConceptScore W2278494804C197934379 @default.
• W2278494804 hasConceptScore W2278494804C2776063141 @default.
• W2278494804 hasConceptScore W2278494804C2776364478 @default.
• W2278494804 hasConceptScore W2278494804C2776694085 @default.
• W2278494804 hasConceptScore W2278494804C2777063308 @default.
• W2278494804 hasConceptScore W2278494804C2777478702 @default.
• W2278494804 hasConceptScore W2278494804C2778375690 @default.
• W2278494804 hasConceptScore W2278494804C2778822529 @default.
• W2278494804 hasConceptScore W2278494804C2778850193 @default.
• W2278494804 hasConceptScore W2278494804C2779609412 @default.
• W2278494804 hasConceptScore W2278494804C2780401358 @default.
• W2278494804 hasConceptScore W2278494804C2781413609 @default.
• W2278494804 hasConceptScore W2278494804C29730261 @default.
• W2278494804 hasConceptScore W2278494804C31760486 @default.
• W2278494804 hasConceptScore W2278494804C71924100 @default.
• W2278494804 hasConceptScore W2278494804C87355193 @default.
• W2278494804 hasConceptScore W2278494804C90924648 @default.
• W2278494804 hasIssue "15_suppl" @default.
• W2278494804 hasLocation W22784948041 @default.
• W2278494804 hasOpenAccess W2278494804 @default.
• W2278494804 hasPrimaryLocation W22784948041 @default.
• W2278494804 hasRelatedWork W1999964913 @default.
• W2278494804 hasRelatedWork W2013163224 @default.
• W2278494804 hasRelatedWork W2111732928 @default.
• W2278494804 hasRelatedWork W2128903704 @default.
• W2278494804 hasRelatedWork W2400769328 @default.
• W2278494804 hasRelatedWork W2403269090 @default.
• W2278494804 hasRelatedWork W2531713994 @default.
• W2278494804 hasRelatedWork W2746429831 @default.
• W2278494804 hasRelatedWork W2751497063 @default.
• W2278494804 hasRelatedWork W3127479238 @default.
• W2278494804 hasVolume "28" @default.
• W2278494804 isParatext "false" @default.
• W2278494804 isRetracted "false" @default.
• W2278494804 magId "2278494804" @default.
• W2278494804 workType "article" @default.